NCT00834080View on ClinicalTrials.gov

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Opiate Dependence
Interventions
DRUG

Medisorb naltrexone 380 mg

Intramuscular (IM) injection administered once every 4 weeks for up to 2 years

Trial Locations (11)

10523

Alkermes Clinical Study Site, Elmsford

19118

Alkermes Clinical Study Site, Philadelphia

19125

Alkermes Clinical Study Site, Philadelphia

33319

Alkermes Clinical Study Site, Lauderhill

44718

Alkermes Clinical Study Site, Canton

60194

Alkermes Clinical Study Site, Hoffman Estates

63109

Alkermes Clinical Study Site, St Louis

75225

Alkermes Clinical Study Site, Dallas

78754

Alkermes Clinical Study Site, Austin

92056

Alkermes Clinical Study Site, Oceanside

92324

Alkermes Clinical Study Site, Colton

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY